MANSFIELD, Mass., Aug. 2, 2011 /PRNewswire/ -- PrimeraDx today announced that Fayyaz Memon has been appointed to the position of Vice President of Regulatory Affairs and Quality Assurance.
"We are very pleased to have Fayyaz join our team during such an exciting period for the Company," stated President and CEO Matthew McManus. "Fayyaz comes at a key time, as we've recently launched our first product based on our unique technology for multiplex quantitative PCR, and we will be going to the FDA for clearance later this year. Fayyaz will bring much needed expertise to take our Quality Systems to the next level and manage our regulatory submissions."
Mr. Memon joins PrimeraDx with over 20 years of experience as an executive in the life sciences and chemical industries. He has held management positions with Thermo Fisher Scientific, Digene, Johnson&Johnson and SmithKline Beecham and has helped numerous companies to obtain FDA clearances and approvals and to establish quality systems. He has a unique background covering quality systems, regulatory affairs, FDA remedial actions, software and process validation, manufacturing, and clinical trial services. Mr. Memon earned his MBA in Operation and Quality Management and MS in Mechanical Engineering from Drexel University.
"It is a very exciting time to join PrimeraDx! Not only has the company recently begun commercialization of its core technology, but we are also poised to be a leader in the field of personalized medicine," commented Mr. Memon. "I believe the product pipeline at PrimeraDx will have a significant impact on patient management, and will help realize the value of genomic medicine."
PrimeraDx is dedicated to the high growth field of molecular diagnostics. The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system. PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners. The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation. The Company's website is: www.primeradx.com or www.multiplexpcr.com.
CONTACT: Andrew Bond, 508-618-2300, [email protected]